Dr. Overman on Updated Findings With Nivolumab in Metastatic CRC

Michael J. Overman, MD
Published: Saturday, Jan 20, 2018



Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer (mCRC) during the 2018 Gastrointestinal Cancers Symposium.

CheckMate-142 evaluated nivolumab (Opdivo) in patients with DNA mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) mCRC. These long-term survival results indicated that nivolumab continued to provide durable and clinically meaningful responses. Additionally, complete response rates increased from 3% to 9%, Overman says.

Previously, there was some flattening on the tail of the progression-free survival (PFS) curve, and Overman says that at follow-up the flattening continued—indicating a median PFS of 44% at 18 months. Of 74 patients evaluable for response, the objective response rate was 34%, and overall survival was 67% at 18 months.

This update supports the idea that nivolumab monotherapy is a durable therapy for this patient population, and may indicated progress toward cure.
 


Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer (mCRC) during the 2018 Gastrointestinal Cancers Symposium.

CheckMate-142 evaluated nivolumab (Opdivo) in patients with DNA mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) mCRC. These long-term survival results indicated that nivolumab continued to provide durable and clinically meaningful responses. Additionally, complete response rates increased from 3% to 9%, Overman says.

Previously, there was some flattening on the tail of the progression-free survival (PFS) curve, and Overman says that at follow-up the flattening continued—indicating a median PFS of 44% at 18 months. Of 74 patients evaluable for response, the objective response rate was 34%, and overall survival was 67% at 18 months.

This update supports the idea that nivolumab monotherapy is a durable therapy for this patient population, and may indicated progress toward cure.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x